[go: up one dir, main page]

MX2012003287A - Uso de la identificacion microambiental de sparc en el tratamiento del cancer. - Google Patents

Uso de la identificacion microambiental de sparc en el tratamiento del cancer.

Info

Publication number
MX2012003287A
MX2012003287A MX2012003287A MX2012003287A MX2012003287A MX 2012003287 A MX2012003287 A MX 2012003287A MX 2012003287 A MX2012003287 A MX 2012003287A MX 2012003287 A MX2012003287 A MX 2012003287A MX 2012003287 A MX2012003287 A MX 2012003287A
Authority
MX
Mexico
Prior art keywords
sparc
micro
cancer treatment
environmental identification
environmental
Prior art date
Application number
MX2012003287A
Other languages
English (en)
Inventor
Vuong Trieu
Neil Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2012003287A publication Critical patent/MX2012003287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención proporciona técnicas basadas en el anticuerpo anti-SPARC multiparamétricos para predecir la respuesta a una terapia, incluyendo quimioterapia, radioterapia, terapia quirúrgica y terapias combinadas.
MX2012003287A 2009-09-18 2010-09-20 Uso de la identificacion microambiental de sparc en el tratamiento del cancer. MX2012003287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27696909P 2009-09-18 2009-09-18
PCT/US2010/049545 WO2011035274A1 (en) 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2012003287A true MX2012003287A (es) 2012-08-03

Family

ID=43759058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003287A MX2012003287A (es) 2009-09-18 2010-09-20 Uso de la identificacion microambiental de sparc en el tratamiento del cancer.

Country Status (13)

Country Link
US (1) US20120245089A1 (es)
EP (1) EP2478362B1 (es)
JP (1) JP2013505268A (es)
KR (1) KR20120092597A (es)
CN (1) CN102576016A (es)
AU (1) AU2010295324B2 (es)
BR (1) BR112012008316A2 (es)
CA (1) CA2774550A1 (es)
IL (1) IL218642A0 (es)
MX (1) MX2012003287A (es)
NZ (1) NZ598801A (es)
WO (1) WO2011035274A1 (es)
ZA (1) ZA201202657B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435068B1 (en) * 2009-05-28 2015-03-04 Abraxis BioScience, LLC Use of 2 anti-sparc antibodies to predict response to chemotherapy
WO2011153485A2 (en) 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Use of the sparc microenvironment signature in the treatment of cancer
CN109906469B (zh) * 2016-11-10 2023-11-21 豪夫迈·罗氏有限公司 基于距离的肿瘤分类

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
CA2519630A1 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
WO2005010213A2 (en) * 2003-07-17 2005-02-03 Pacific Edge Biotechnology, Ltd. Markers for detection of gastric cancer
EP1704250B1 (en) * 2003-12-31 2012-09-19 The Penn State Research Foundation Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
JP4834839B2 (ja) * 2004-10-19 2011-12-14 国立大学法人 熊本大学 悪性黒色腫（メラノーマ）の新規な診断キット
KR101976003B1 (ko) * 2005-02-18 2019-05-09 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
AU2006237613A1 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 SPARC deletion mutant and uses thereof
CN105418751B (zh) * 2006-06-16 2019-03-05 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
ES2700074T3 (es) * 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
EP2134864A4 (en) * 2007-03-09 2012-04-11 Univ British Columbia ASSESSMENT OF THE RESISTANCE OF COLORECTAL TUMORS TO CHEMOTHERAPY BY DETERMINING SPARC HYPERMETHYLATION
CA2683973A1 (en) * 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer

Also Published As

Publication number Publication date
EP2478362A4 (en) 2013-09-11
KR20120092597A (ko) 2012-08-21
BR112012008316A2 (pt) 2017-06-06
ZA201202657B (en) 2013-09-25
NZ598801A (en) 2014-07-25
IL218642A0 (en) 2012-05-31
EP2478362A1 (en) 2012-07-25
CA2774550A1 (en) 2011-03-24
AU2010295324A1 (en) 2012-04-05
WO2011035274A1 (en) 2011-03-24
JP2013505268A (ja) 2013-02-14
EP2478362B1 (en) 2016-05-11
AU2010295324B2 (en) 2015-04-30
US20120245089A1 (en) 2012-09-27
CN102576016A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
CY2024023I1 (el) Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
TWD161529S (zh) 治療燈
EA201791843A3 (ru) Способы повышения эффективности folr1 терапии рака
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
EA201400178A1 (ru) Лечение рака молочной железы
CL2015002807A1 (es) Terapia de combinación
CL2015002369A1 (es) Uso de linagliptina en terapia antidiabética cardio y renoprotectora
MX379463B (es) Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
PL3489261T3 (pl) Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
SG11201602070TA (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
EA201201474A1 (ru) Способы лечения рака молочной железы
EA201890598A2 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
ECSP14013195A (es) Catéter, en particular catéter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la próstata.
BR112015010220A2 (pt) métodos de utilização de biomarcadores para tratamento de câncer
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX2013006758A (es) Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
MX2014010714A (es) Terapia de combinacion de procaspasa para gliobastoma.
EA200970885A1 (ru) Комбинирование лечения рака с применением il-18 человека и антитела против cd20
MX2015010740A (es) Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix).
BR112017025533A2 (pt) método para tratar câncer em um paciente humano

Legal Events

Date Code Title Description
FA Abandonment or withdrawal